S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
Is Gold Really Boring? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: World shares mixed after Wall Street retreat deepens
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
Is Gold Really Boring? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: World shares mixed after Wall Street retreat deepens
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
Is Gold Really Boring? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: World shares mixed after Wall Street retreat deepens
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
Is Gold Really Boring? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: World shares mixed after Wall Street retreat deepens
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
US consumer confidence tumbles in September as American anxiety about the future grows
NASDAQ:FOLD

Amicus Therapeutics (FOLD) Stock Forecast, Price & News

$12.24
+0.28 (+2.34%)
(As of 09/26/2023 ET)
Compare
Today's Range
$12.04
$12.47
50-Day Range
$11.96
$13.86
52-Week Range
$9.10
$14.10
Volume
1.68 million shs
Average Volume
1.88 million shs
Market Capitalization
$3.51 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.20

Amicus Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
24.2% Upside
$15.20 Price Target
Short Interest
Bearish
6.84% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.28
Upright™ Environmental Score
News Sentiment
1.02mentions of Amicus Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$1.65 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.43) to $0.08 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.76 out of 5 stars

Medical Sector

775th out of 963 stocks

Pharmaceutical Preparations Industry

360th out of 448 stocks


FOLD stock logo

About Amicus Therapeutics (NASDAQ:FOLD) Stock

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

FOLD Price History

FOLD Stock News Headlines

Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Amicus Therapeutics Names Simon Harford New CFO With Immediate Effect
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Amicus Therapeutics Inc (AM6.SG)
Amicus Therapeutics Q2 2023 Earnings Preview
3 Top Biotech Stocks to Purchase Right Away
See More Headlines
Receive FOLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FOLD Company Calendar

Last Earnings
8/08/2023
Today
9/27/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:FOLD
CUSIP
03152W10
Employees
484
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$15.20
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+24.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-236,570,000.00
Pretax Margin
-55.06%

Debt

Sales & Book Value

Annual Sales
$329.23 million
Book Value
$0.44 per share

Miscellaneous

Free Float
281,091,000
Market Cap
$3.51 billion
Optionable
Optionable
Beta
0.86

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. John F. CrowleyMr. John F. Crowley (Age 56)
    Exec. Chairman
    Comp: $1.88M
  • Mr. Bradley L. Campbell M.B.A.Mr. Bradley L. Campbell M.B.A. (Age 47)
    CEO, Pres & Director
    Comp: $984.09k
  • Ms. Ellen S. Rosenberg (Age 60)
    Chief Legal Officer & Corp. Sec.
    Comp: $733.94k
  • Mr. David M. Clark (Age 48)
    Chief People Officer
    Comp: $701.39k
  • Ms. Daphne E. Quimi CPA (Age 57)
    M.B.A., Sr. VP of Fin.
    Comp: $748.4k
  • Dr. Jeffrey P. Castelli (Age 51)
    Chief Devel. Officer
    Comp: $709.64k
  • Mr. Simon Nicolas Reade Harford (Age 62)
    Chief Financial Officer
  • Ms. Samantha Prout (Age 45)
    Chief Accounting Officer & Controller
  • Dr. Jill Weimer Ph.D.
    Chief Science Officer
  • Andrew Faughnan
    Sr. Director of Investor Relations













FOLD Stock - Frequently Asked Questions

Should I buy or sell Amicus Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" FOLD shares.
View FOLD analyst ratings
or view top-rated stocks.

What is Amicus Therapeutics' stock price forecast for 2023?

5 Wall Street analysts have issued 12-month price targets for Amicus Therapeutics' shares. Their FOLD share price forecasts range from $11.00 to $17.00. On average, they expect the company's share price to reach $15.20 in the next year. This suggests a possible upside of 24.2% from the stock's current price.
View analysts price targets for FOLD
or view top-rated stocks among Wall Street analysts.

How have FOLD shares performed in 2023?

Amicus Therapeutics' stock was trading at $12.21 at the beginning of 2023. Since then, FOLD stock has increased by 0.2% and is now trading at $12.24.
View the best growth stocks for 2023 here
.

When is Amicus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our FOLD earnings forecast
.

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.03. The biopharmaceutical company earned $94.50 million during the quarter, compared to analysts' expectations of $89.57 million. Amicus Therapeutics had a negative net margin of 52.85% and a negative trailing twelve-month return on equity of 157.79%.

What is John F. Crowley's approval rating as Amicus Therapeutics' CEO?

21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.34%), JPMorgan Chase & Co. (4.72%), State Street Corp (3.89%), Point72 Asset Management L.P. (2.44%), Geode Capital Management LLC (1.90%) and Fiera Capital Corp (1.75%). Insiders that own company stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, David Michael Clark, Ellen Rosenberg, Hung Do, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends
.

How do I buy shares of Amicus Therapeutics?

Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amicus Therapeutics' stock price today?

One share of FOLD stock can currently be purchased for approximately $12.24.

How much money does Amicus Therapeutics make?

Amicus Therapeutics (NASDAQ:FOLD) has a market capitalization of $3.51 billion and generates $329.23 million in revenue each year. The biopharmaceutical company earns $-236,570,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis.

How many employees does Amicus Therapeutics have?

The company employs 484 workers across the globe.

How can I contact Amicus Therapeutics?

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The official website for the company is www.amicusrx.com. The biopharmaceutical company can be reached via phone at (215) 921-7600, via email at afaughnan@amicusrx.com, or via fax at 609-662-2001.

This page (NASDAQ:FOLD) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -